YK11
Where to buy YK11 pills ?
In 2011, Yk11 was first studied by a Japanese researcher Yuihi Kanno. It is a novel steroid compound (YK11) is a partial agonist of the Androgen Receptor (AR). YK11 is one of the most myostatin inhibitor on the market [1].
YK11 does not include amino/carboxyl-terminal interaction and prevents 5-α-dihydrotestosterone (DHT)-mediated N/C interaction. Thus, YK11 speeds up nuclear translocation of AR. YK11 activates AR without amino/carboxyl-terminal interaction. In addition, YK11 attaches to the androgen receptor to inhibit the production of myostatin in the muscle and helps to build FST and increase the muscle growth [2].
The consumption of YK11 and dihydrotestosterone (DHT) speed up cell proliferation and mineralization in mouse osteoblast cells. YK11 increased osteoblast specific differentiation markers. In [3], the authors show that YK11 causes increasing in cell growth. In addition, YK11 is considered as myostatin inhibitor so that it decreases the level of pro-inflammatory cytokines and organ damage markers and decreases the mortality rate. Thus, YK11 helps in revert muscle wasting in inflammatory environment.
No one negative feedback about our store in the last five years
[1] Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17α, 20E)-17, 20-[(1-Methoxyethylidene) bis (oxy)]-3-oxo-19-norpregna-4, 20-diene-21-carboxylic Acid Methyl Ester (YK11) Is a Partial Agonist of the Androgen Receptor. Biological and Pharmaceutical Bulletin. 2011 Mar 1;34(3):318-23.
[2] Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biological and Pharmaceutical Bulletin. 2013 Sep 1;36(9):1460-5.
[3] Yatsu T, Kusakabe T, Kato K, Inouye Y, Nemoto K, Kanno Y. Selective androgen receptor modulator, yk11, up-regulates osteoblastic proliferation and differentiation in mc3t3-e1 cells. Biological and Pharmaceutical Bulletin. 2018 Mar 1;41(3):394-8.